KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.
about
Comparison of K-ras mutations in lung, colorectal and gastric cancer.Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancerProspective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patientsDiagnostic RAS mutation analysis by polymerase chain reaction (PCR).Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatmentsHotspot oncomutations: implications for personalized cancer treatment.KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.Toxicogenomics and cancer susceptibility: advances with next-generation sequencing.RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.Improved detection of BRAF V600E using allele-specific PCR coupled with external and internal controllers.Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.Reply: KRAS mutation in colorectal cancer metastases after adjuvant folfox for the primary.Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
P2860
Q33843263-64A8558D-7390-46A2-927D-83A35B427C7FQ34978610-49EA16FE-4990-4ECF-9EDA-5869036F26A7Q35800764-7A0181FC-434E-46AA-A0E2-F0A242555427Q35877954-18425B16-7EFA-46BD-ABE4-30801A5028A8Q36089917-8795B939-94F0-486F-A87B-E7C5991AE9F5Q36166765-4A3C6E1B-2AB1-457C-8517-D38702022E03Q36545624-5C2FF075-04EB-417C-981E-46C026C63E22Q37000019-FEFA318B-6380-4950-A7D8-E79ABD3E0B94Q37098291-4C5D3587-717E-4756-A4A8-00CA3436C4C2Q37423355-DF1EF450-8107-44A7-8BE1-6E7E1C39025BQ38030603-9A70C445-C25A-47D5-BFE4-232C4B8FC134Q38136134-23603E72-8068-4BF6-8DF4-3AC3F1F64EB1Q38215923-B106B896-BF93-46FB-B699-3BC72BDBF544Q43531971-6C8D7D06-8AB7-4496-90F9-F7179169CA45Q43812432-0A1EBE1E-0B94-4CE2-A6BB-2BEEF2ECCF47Q44504622-D957E575-C53B-4EC7-B5CE-8C7B539493D8Q45376093-72BBFD29-F9E6-4B41-89C4-19AA38E9FE6DQ45940227-CF80F3DB-AD09-401C-B7C6-363A3A4BDE58Q46102946-2963633B-7DDD-42E9-BAED-0728BA5BA813
P2860
KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@ast
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@en
type
label
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@ast
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@en
prefLabel
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@ast
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@en
P2093
P2860
P356
P1476
KRAS mutations detected by the ...... erapeutic effect of cetuximab.
@en
P2093
K Tsuchihara
N Ogasawara
P2860
P2888
P304
P356
10.1038/BJC.2011.247
P407
P577
2011-07-05T00:00:00Z